A ntiretroviral therapy (ART) consists of a combination of drugs targeting the human immunodeficiency virus (HIV) life cycle with the aim of stopping HIV replication and preserving or restoring immune function. Since publication of the last recommendations in 2012, 1 there is more evidence supporting the initiation of ART regardless of CD4 cell count. New cohort data provide compelling evidence for the effectiveness of treatment to prevent transmission in heterosexual and same-sex couples. [2] [3] [4] In addition, morbidity and mortality from non-AIDS-defining illness did not differ from that of the general population if CD4 cell counts of greater than 500/μL were achieved. 5 Several reports suggest that if ART is started early during acute infection, prolonged virologic suppression after discontinuation of ART may be achievable in rare cases. 6, 7 New drugs with high potency, low toxicity, and good tolerability increase the feasibility of early, lifelong treatment. Even patients with prior treatment failure and multidrug resistance can usually be treated with suppressive ART. Recommendations provided herein for the optimal management of adults with HIV infection are based on the latest developments and available evidence.
Methods
These recommendations were developed by a volunteer, international panel of experts in HIV research and patient care selected by the International Antiviral Society-USA and vetted for suitability, expertise, conformance to the group's conflict of interest criteria, and ability to work toward consensus. The panel convened in person and by conference calls in 2013 and 2014. Section leaders and teams evaluated evidence and summarized draft recommendations for full-panel review. Evidence used was published in the scientific literature, presented at major peer-reviewed scientific conferences, or released as safety reports by regulatory agencies or data and safety monitoring boards since 2012. 1 Literature searches in PubMed and EMBASE by reference librarians were designed to capture publications relevant to ART in HIV infection since the 2012 iteration 1 through June 2014. Approximately 400 relevant citations were identified. Relevant abstracts publicly presented at scientific conferences were identified by panel members. Manufacturers of antiretroviral drugs submitted lists of recent publications or abstracts meeting the established criteria. These recommendations are focused on adults with HIV infection living in settings in which antiretroviral drugs are generally available (approved by regulatory bodies or in expanded access) or in latestage development (new drug application filed). Recommendations were made by full-panel consensus and rated ( Table 1) . For areas in which recommendations have not changed substantially or no or few new data are available, the reader is referred to the previous report. 1 Further details about the process, the selection of panel members, the sponsor (International Antiviral Society-USA), and its policies are included in the eMethods, in eBoxes 1-4, and in eTables 1-3 in the Supplement.
Recommendations for When to Start
Additional evidence for initiating ART in all adults with HIV infection has emerged from continued observational cohort data, 5,9-11 the lack of demonstrated harm with early initiation, cost-effectiveness modeling, and data from a randomized clinical trial showing that ART reduced the likelihood of HIV transmission while providing clinical benefit to the individual. [2] [3] [4] [12] [13] [14] [15] Recommendations for when to start ART appear in Box 1. The strength of the recommendations and the quality of the evidence increase as CD4 cell counts decrease and in the presence of certain concurrent conditions. The World Health Organization recommends ART be initiated regardless of CD4 cell count for a number of clinical and programmatic indications. 16 The patient must be willing and ready to initiate therapy. Medication counseling and adherence support should be offered. However, patients who do not choose or are not ready to start ART should remain in clinical care with regular monitoring and ongoing discussion about the need for ART.
The evidence for initiating ART in patients termed elite controllers (ie, those with an HIV-1 RNA level of less than the level of detection without ART) is stronger than in the past, [17] [18] [19] but still insufficient to warrant recommending routine treatment.
Acute HIV Infection
ART is recommended for persons with acute HIV infection, and should be started as soon as possible to maximize benefit. 7 New data have demonstrated additional benefits of ART, namely reduction of proviral DNA and plasma viral load, 20,21 lower viral set point, 22 robust immune reconstitution, 21 and CD4 cell count increases greater than 900/μL. 23 Patients in these trials received ART for a limited period ranging from 12 to 60 months. None of the above benefits lasted for more than 24 months after treatment discontinuation. 24 ART did not prevent persistent T-cell activation, 25 but did reduce the generation of latently infected cells, 26 and in anecdotal cases, led to prolonged viral suppression after discontinuation of ART. 6, 7 ART should be offered to all patients with acute or early infection. Planned discontinuation of ART after a specific duration of treatment is not recommended except in research settings. 30 The recently published COAT trial demonstrated higher mortality in the 2-to 5-week period after randomization in those receiving early vs delayed ART, with the most pronounced difference observed in those with CD4 cell counts of less than 50/μL and severe cryptococcal meningitis with white blood cell counts of less than 5/μL in cerebrospinal fluid. 31 The excess mortality was not explained by other differences, including the occurrence of ART is recommended regardless of CD4 cell count (AIa-BIII). The strength of the recommendation increases as the CD4 cell count decreases and in the presence of certain conditions, with the following ratings:
For CD4 cell counts of Յ500/μL: AIa For CD4 cell counts of >500/μL: BIII Ratings for specific conditions with CD4 cell counts of >500/μL:
Pregnancy: AIa Chronic hepatitis B virus co-infection: AIIa HIV-associated nephropathy: AIIa ART is recommended and should be offered to persons during the acute phase of primary HIV infection, regardless of symptoms (BIII).
ART should be started as soon as possible, preferably within the first 2 weeks of diagnosis, in patients with opportunistic infections (AIa) and other opportunistic diseases and AIDS-defining illnesses (including all lymphomas and human papillomavirus-related cancers) (AIa-BIII).
The optimal timing for patients with cryptococcal meningitis is less certain, but initiating ART early during cryptococcal treatment should be considered when expert management of both cryptococcal and HIV infection is available (BIII).
ART is recommended in all HIV-infected persons with tuberculosis (TB) and should be started within 2 weeks of TB treatment when the CD4 cell count is <50/μL, and by 8 to 12 weeks for those with higher CD4 cell counts (AIa). The optimal timing for patients with TB meningitis is less certain, but ART should be started within the first 2 to 8 weeks of diagnosis and managed in consultation with experts (BIII).
Recommendations for ART Monitoring
HIV-1 RNA level should be monitored at about 4 weeks after treatment is initiated or changed, and then every 3 months to confirm suppression of viremia below the limit of quantification of sensitive commercial assays (AIa).
CD4 cell count should be monitored at least every 3 months after initiation of therapy, especially among patients with cell counts of <200/μL, to determine the need for initiation or discontinuation of primary opportunistic infection prophylaxis (BIII).
Once HIV-1 RNA level is suppressed for 1 year and CD4 cell count is stable at Ն350/μL, viral load and CD4 cell count can be monitored at intervals of Յ6 months in patients with dependable adherence (CIII).
Once viral load is demonstrated to be suppressed consistently for more than 2 years and CD4 cell counts are persistently >500/μL, monitoring CD4 cell counts is optional unless virologic failure occurs or there are intercurrent immunosuppressive treatments or conditions (CIII). Detectable HIV-1 RNA level (>50 copies/mL) during therapy should be confirmed within 4 weeks in a subsequent sample prior to making management decisions (BIII).
HIV-1 RNA level >200 copies/mL should prompt evaluation of factors leading to failure and consideration of switching ART (AIIa).
Baseline genotypic testing for resistance should be performed in all treatment-naive patients (AIIa) and in cases of confirmed virologic failure (AIa).
Therapeutic drug monitoring is not recommended in routine care; however, selected patients might benefit from this intervention (BIII).
Laboratory monitoring for ART toxicity is recommended. In the absence of new abnormalities after week 16 of treatment, the frequency of monitoring, which is generally between 3 and 6 months, should be guided by the presence or absence of comorbidities, and by the components of the regimen (CIII).
Recommendations for Changing the ART Regimen in Treatment-Experienced Patients
Design of a new regimen should consider previous antiretroviral therapy exposure, previous resistance profile, drug interactions, and history of intolerance or toxic effects (AIIa).
Depending on the resistance profile, viral tropism, and options available for patients with multidrug resistance, inclusion of a boosted protease inhibitor and agents from newer drug classes (eg, an integrase strand transfer inhibitor or maraviroc) should be considered (AIa).
Monotherapy with a boosted protease inhibitor is not recommended when other options are available (AIa).
Maintenance of virologic suppression is paramount when switching the regimen to improve tolerability, reduce toxicity, and improve convenience (AIa).
Switching or regimen simplification in virologically suppressed individuals is generally safe if prior treatment and resistance profile are considered and full activity of the nucleoside reverse transcriptase inhibitors can be ensured for switches from a ritonavir-boosted protease inhibitor to drugs with low barriers to resistance (nonnucleoside reverse transcriptase inhibitors, unboosted protease inhibitors, or integrase strand transfer inhibitors) (AIa).
a Ratings of the strength of the recommendations and quality of evidence are described in Table 1. IRIS between the 2 groups. Most deaths were attributed to progressive cryptococcal meningitis, although it was not possible to differentiate IRIS from progressive cryptococcal disease. These data suggest that caution when initiating ART in the setting of cryptococcal meningitis is warranted. Earlier initiation of ART (before 5 weeks) might be considered in settings in which there is access to appropriate antifungal therapy (including flucytosine), 32 frequent monitoring, appropriate management of high intracranial pressure, and careful management of other underlying conditions that might influence mortality.
Cost
The cost of ART varies globally, but even in resource-rich countries ART is highly cost-effective. [33] [34] [35] In the United States, cost of care for patients with more advanced disease (eg, CD4 cell count <50/ μL) is 2.5-fold higher (expenditure/patient/year) than for those with higher (>350/μL) CD4 cell counts. 36 In resource-limited settings, ART is even more cost-effective because of much lower medication costs.
13
In the next 4 years, more than 20 drugs are expected to become available in generic form (eTable 4 in the Supplement). A modeling study has estimated substantial reductions in expenditures and improved cost-effectiveness will occur when generic drugs are used.
14 However, some of the newer agents have efficacy or tolerability advantages over drugs that will soon become generic. In addition, the use of generic drugs may require that patients switch from single-tablet regimens to multiple-pill regimens, which could adversely affect adherence.
Recommendations for What Treatment to Start
Data that inform choices for initial ART continue to accrue, and options for ART-naive patients include several single-tablet regimens and other efficacious regimen choices ( Table 2 and Table 3 ). Large studies have expanded knowledge of ART anchored by integrase strand transfer inhibitors (INSTIs), 37-45 and several INSTI-based regimens are now recommended. At present, ART is considered lifelong, and sustained viral suppression is the foundation for immune recovery, optimal health, and prevention of resistance and transmission. Thus, maximizing adherence and minimizing toxicity is paramount; the goal is to treat with an effective therapy that is well tolerated and convenient, and has limited drug interactions and effects on comorbid conditions. In e The combination of abacavir and lamivudine was less efficacious with baseline HIV-1 RNA level above 100 000 copies/mL than the combination of tenofovir and emtricitabine when these agents were given with efavirenz or ritonavir-boosted atazanavir. f Rilpivirine should not be given with proton pump inhibitors and should be taken consistently with a full meal. g Should be taken with food.
h Co-administration with H2-blockers or proton pump inhibitors should be avoided if possible and, if not, specific doses and dose separation schedules are recommended as per prescribing information.
whereas in resource-limited settings, a public health approach as described in the World Health Organization guidelines 47 has been adopted. Ideally, definitive studies to determine the optimal regimen for the majority of ART-naive patients would simplify treatment strategies. However, such studies would be costly and are unlikely to be conducted. Wider availability of effective generic drugs 14 and the development of comorbid conditions as patients age will have a strong influence on initial ART choice. Initial ART, selected based on baseline resistance testing and patient characteristics and preference, continues to be based on a combination of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent, either an INSTI, a nonnucleoside reverse transcriptase inhibitor (NNRTI), or a boosted protease inhibitor (PI). Since the 2012 recommendations, 1 several large trials have expanded and refined initial ART choices. [37] [38] [39] [40] [41] [42] [43] [44] [48] [49] [50] [51] In addition, data from wellpowered comparative studies of combinations that limit or spare NRTI exposure 52,53 provide evidence for ART choices when inclusion of an NRTI poses a substantial toxic effect risk. In settings in which the use of generic drugs is not required, 3 (and soon to be 4) co-formulated, once-daily, single-tablet regimens are now available. Recommended and alternative regimens are listed in Table 2 and Table 3 . The clinical situations in which alternative regimens are needed are limited.
Nucleoside Reverse Transcriptase Inhibitors
Two fixed-dose, NRTI combinations (in alphabetic order), abacavir/ lamivudine and tenofovir disoproxil fumarate/emtricitabine, were generally chosen as the NRTI components in randomized trials of initial therapy in the recent past.
Recommended
Abacavir should only be used in HLA-B*5701-negative individuals. Whether this drug carries an increased risk of myocardial infarction (MI) remains uncertain. An association of abacavir with MI has been demonstrated in some observational studies, 54,55 but not in others.
56
A US Food and Drug Administration meta-analysis of randomized clinical trials found no appreciable risk of MI compared with alternative NRTIs in patients with low cardiovascular risk initiating abacavir-containing therapy with a median follow-up of 1.5 years. 57 An updated analysis from the cohort collaboration that originally reported the association of abacavir with MI in 2008 recently reconfirmed the results with data updated through 2012, despite evidence that those at higher risk for cardiovascular disease were less served with abacavir/lamivudine paired with dolutegravir or raltegravir.
37-39,60
Tenofovir and emtricitabine are available in 3 single-tablet regimens in addition to the fixed-dose combination of the 2 NRTIs. This combination is well tolerated but, as outlined in the previous recommendations, long-term use of tenofovir is associated with increased risk of kidney injury, which is accentuated by concomitant use of boosted PIs and is typically but not always reversible with discontinuation if detected early. 61 Patients should be monitored regularly for glomerular and tubular injury. Although most ART regimens are associated with an early and nonprogressive decrease in bone mineral density (BMD), this decrease is more pronounced with tenofovir. Long-term efficacy and safety data have continued to accumulate for emtricitabine, and no new or unexpected adverse events have been reported.
Alternative
Twice-daily fixed-dose combination zidovudine/lamivudine may be considered for the individual who is unable to receive abacavir or tenofovir for tolerability or safety reasons and for whom an NRTI is considered necessary.
Integrase Strand Transfer Inhibitors
Dolutegravir once daily, elvitegravir with cobicistat once daily, and raltegravir twice daily are potent antiretroviral drugs that are well tolerated in combination with NRTIs. Compared with NNRTI-based or boosted PI-based regimens, these agents have consistently shown higher rates of viral suppression, which in several studies reached statistical superiority. 37, 44, 62 The drugs are discussed in alphabetic order.
Recommended
Dolutegravir is a once-daily INSTI that does not require pharmacological boosting and has similar activity and safety to raltegravir when combined with tenofovir/emtricitabine or abacavir/lamivudine.
38,39
Dolutegravir plus abacavir/lamivudine was superior to the fixeddose combination of efavirenz/tenofovir/emtricitabine with the difference driven by nonvirologic end points. Rilpivirine in a fixed-dose combination with tenofovir/ emtricitabine is recommended for individuals with pretreatment plasma HIV-1 RNA levels of less than 100 000 copies/mL. 50,51 Risk of NRTI-and NNRTI-class resistance with virologic failure is greater with failure of rilpivirine-based than with efavirenz-based therapy, and rilpivirine-resistant variants are likely to be cross-resistant to all available NNRTIs.
67

Alternatives
Rilpivirine with abacavir/lamivudine is an alternative regimen. A 400-mg dose of efavirenz may have reduced adverse effects with similar efficacy. 68 Nevirapine-based ART remains an alternative if baseline CD4 cell count criteria are met. 1 
Protease Inhibitors
Protease inhibitors are used in combination with 2 NRTIs for initial ART. In most cases, co-administration with either ritonavir or cobicistat is required to boost PI levels through inhibition of the cytochrome P450 3A4 (CYP3A4) enzyme. As a class, PIs are associated with mild to moderate nausea, diarrhea, and dyslipidemia. However, these adverse effects occur less frequently with newer PIs. All PIs may be associated with cardiac conduction abnormalities, particularly PR prolongation.
69
Recommended Ritonavir-boosted atazanavir is used in initial therapy once daily. The atazanavir-boosted regimen blocks bilirubin conjugation, resulting in an elevation in unconjugated (indirect) bilirubin, which can cause jaundice in some individuals but does not represent hepatotoxicity. Unboosted atazanavir has reduced potency and is generally not renal impairment. 61, 72 It is the only ritonavir-boosted PI shown to be noninferior to efavirenz in a large randomized trial 73 and was not associated with MI in a large cohort analysis. 74 However, ritonavirboosted atazanavir was inferior to ritonavir-boosted darunavir and raltegravir in a large randomized open-label trial, primarily because of discontinuations due to increased bilirubin.
44
Ritonavir-boosted darunavir is used once daily in initial regimens. Darunavir contains a sulfa moiety, and rashes occurred in approximately 10% of patients during clinical trials. Darunavir should be used with caution in patients with severe sulfa allergies.
Alternative
Ritonavir-boosted lopinavir is an alternative that has more adverse effects than darunavir or atazanavir and is associated with increased cardiovascular risk. 1 Following the expected availability of cobicistat as a stand-alone booster, it will be possible to use it as an alternative to ritonavir to boost darunavir and atazanavir, and coformulations of cobicistat with either PI are expected to follow. In a randomized trial comparing cobicistat with ritonavir as boosters for atazanavir, efficacy and tolerability were comparable.
75
NRTI-Sparing Therapy
There are clinical situations in which minimizing or eliminating NRTI exposure is desirable (eg, a patient with high risk of cardiovascular disease or a positive HLA-B*5701 assay who also has chronic kidney disease or osteoporosis). Results from well-powered, controlled studies comparing NRTI-sparing or NRTI-limiting regimens with standard combination therapy are now available.
Alternatives
Ritonavir-boosted darunavir once daily with raltegravir twice daily was noninferior to ritonavir-boosted darunavir plus tenofovir/ emtricitabine in a large randomized study. 53 However, in patients with CD4 cell counts of less than 200 cells/μL, ritonavir-boosted darunavir plus raltegravir was less efficacious. 53 Twice-daily ritonavirboosted lopinavir plus lamivudine was compared with ritonavirboosted lopinavir plus lamivudine and another NRTI, and demonstrated comparable viral suppression at 48 weeks. 52 Of the patients in the comparator group, 53.9% received zidovudine as the second NRTI, which limits the study's applicability to resource-rich settings. Twice-daily ritonavir-boosted lopinavir with raltegravir is an NRTI-sparing alternative that had similar efficacy to ritonavirboosted lopinavir with tenofovir/emtricitabine in a small trial in which only 16.5% of patients had HIV-1 RNA levels of greater than 100 000 copies/mL. 76 A large study comparing ritonavir-boosted darunavir plus maraviroc with ritonavir-boosted darunavir plus tenofovir/ emtricitabine was stopped due to the inferior efficacy of the maraviroc group, 77 a reminder that any NRTI-sparing regimen must be evaluated carefully.
Special Considerations Pregnancy
ART should be initiated in all HIV-infected women who became pregnant. The rate of congenital birth defects following exposure to ART during pregnancy is not higher than that reported in the general population and is not greater with exposure during the first trimester than later during the pregnancy. The choice of initial regimens is influenced by chronic and acute comorbid conditions. Specific antiretroviral drugs may exacerbate comorbid conditions or increase the risk of negative clinical outcomes. Comorbidities may increase the likelihood of antiretroviral drug toxicity, and treatment for these conditions may have substantial 1-or 2-way interactions with ART.
Cardiovascular, Renal, and Bone Diseases
As noted in the 2012 recommendations, 1 consideration should be given to avoiding use of abacavir, ritonavir-boosted lopinavir, and ritonavir-boosted fosamprenavir in persons at high risk for cardiovascular disease because these regimens have been associated with increased risk of cardiovascular events in some studies. In a large randomized trial of treatment-naive patients, raltegravir had less adverse effects on lipids than either ritonavir-boosted atazanavir or ritonavir-boosted darunavir combined with tenofovir/emtricitabine. 83 Similarly, dolutegravir plus abacavir/ lamivudine was associated with fewer adverse lipid changes than efavirenz/tenofovir/emtricitabine, 37 and elvitegravir/cobicistat/ tenofovir/emtricitabine had less effect on lipids than efavirenz/tenofovir/emtricitabine. 40 Taken together, these data suggest that INSTI-based regimens may be a good option for patients with preexisting dyslipidemia.
Patients with reduced renal function should generally avoid tenofovir, especially in combination with a boosted PI.
61,84 Initiation of elvitegravir/cobicistat/tenofovir/emtricitabine is not recommended for patients with an estimated creatinine clearance of less than 70 mL/min, and discontinuation is recommended if creatinine clearance is less than 50 mL/min.
85
As noted in the 2012 recommendations, 1 the prevalence of osteoporosis and incidence of fragility fracture are increased with HIV infection. Initiation of ART generally results in a 2% to 6% loss of BMD over the following 1 to 2 years. Loss of BMD is greater with tenofovir than with abacavir, 86 and less with raltegravir than with ritonavir-boosted atazanavir or ritonavir-boosted darunavir when combined with tenofovir/emtricitabine. 87 In a randomized, or rifabutin based on a pharmacokinetic study of rifamycin administered with 50 mg of dolutegravir given twice daily in healthy volunteers. 99 However, dolutegravir has not been studied in HIVinfected individuals with active TB. There are no data on elvitegravir/cobicistat with rifamycin drugs, but these drugs should not be used together because of a likely interaction. A 3-month, once-weekly regimen of isoniazid with rifapentine for treatment of latent TB infection is as effective as 9 months of isoniazid alone. 100 This regimen has now also been shown to be equally effective in HIV-infected individuals. 101 As with rifampin, pharmacokinetic data from an ongoing study indicate that high-dose daily rifapentine can be safely administered with efavirenz, suggesting that the 3-month regimen of weekly isoniazid and rifapentine for latent TB infection can also be given together with efavirenz-based ART.
102
Bedaquiline, a diarylquinoline antimycobacterial drug, has recently been approved by the US Food and Drug Administration for treatment of multidrug-resistant TB, 103 in combination with other active agents. There are no data on bedaquiline use in HIV-infected persons receiving ART. If bedaquiline use is anticipated in an HIVinfected patient receiving ART, expert consultation is recommended.
Hepatitis B Virus Infection
Recommended ART for persons co-infected with HIV and hepatitis B virus includes tenofovir and emtricitabine (or lamivudine) as the fundamental NRTI. If a co-infected patient has moderate kidney disease (creatinine clearance, 30-49 mL/min/1.73 m 2 ), then tenofovir/ emtricitabine may be used every other day provided the kidney injury is not secondary to tenofovir. Entecavir is an alternative to tenofovir if used with suppressive ART.
Malignancy and Immunosuppressive Treatment
Anticancer and immunosuppressive drugs (including long-acting corticosteroids) and ART often have overlapping toxic effects, and there is potential for substantial drug interactions. Because of their favorable drug interaction profiles, dolutegravir-or raltegravir-based regimens are recommended in this setting.
Hepatitis C Virus Infection
In the setting of co-infection with HIV and HCV, selection of optimal ART is determined by potential drug interactions between ART and HCV treatments. Drug interactions between ART and directacting antivirals for HCV are common because many of these drugs are substrates of CYP450 or membrane transporters such as Pglycoprotein. Also, many of these agents are either inhibitors or inducers of these systems, leading to increased or decreased plasma concentrations. 104 Research-based assays identify many treated patients with residual viremia of 1 to 10 copies/mL despite optimal ART adherence.
114
Studies using observational databases suggest that patients with HIV-1 RNA levels of less than 40 copies/mL but with detectable viremia have poorer virologic outcomes than those with no detectable HIV-1 RNA. 115, 116 However, other studies indicate that individuals with at least 2 reported HIV-1 RNA levels of 20 to 50 copies/mL during 1 year of follow-up did not have higher rates of failure than fully suppressed patients. 117 Persistent HIV-1 RNA levels of 50 to 200 copies/mL were associated with increased risk of virologic failure, 118 although not in a recent large observational study. 119 A first detectable HIV-1 RNA level of greater than 50 copies/mL during therapy should be confirmed in a subsequent sample within 4 weeks to exclude treatment failure prior to making management decisions. There are insufficient data to make general recommendations for the management of patients with sustained viremia of 50 to 200 copies/ mL. Whether to alter therapy in this situation should be considered carefully and may depend on individual patient characteristics, treatment history, current ART regimen, and resistance data.
New resistance mutations were detected in 16% to 65% of participants with persistent HIV-1 RNA levels of less than 1000 copies/mL. 1, 120 Drug resistance in that setting is strongly associated with subsequent virologic failure. 121 Genotyping of low-level viremia samples can be performed with a reasonably high success rate, 122,123 which has led some to recommend resistance testing in such circumstances.
123
All newly diagnosed patients should have reverse transcriptase and protease resistance performed as soon as possible after diagnosis and before initiation of ART. Transmitted resistance may be underestimated if testing is not performed early after infection.
124
Patients with mutations detected prior to ART initiation have a 3-to 5-fold greater risk of virologic failure if a drug to which the virus is resistant is used. 125 Routine integrase genotyping is not generally recommended but should be considered if there is widespread use of this drug class and a lack of surveillance data for primary integrase resistance. For confirmed virologic failure, resistance testing is essential and should be performed while the patient is still receiving the failing regimen when possible. 
Treatment-Experienced Patients
Management of Virologic Failure
Recommendations for changing the regimen in treatmentexperienced patients appear in Box 1. With increased availability of new drugs and regimens, the goal of sustained suppression should be achievable in most individuals. The principles and approach to virologic failure are unchanged from the 2012 guidelines. 1 When constructing a new regimen in the setting of virologic failure, the potential reasons for failure should be considered, including adverse effects, exacerbation of comorbidities, drug interactions, pill burden, and dosing frequency, all of which can affect adherence. New regimens are constructed based on treatment history, reasons for nonadherence, and the results of previous and current resistance tests. Interpretation of mutations and cross-resistance can be complex and expert advice should be sought.
Failure of Initial ART Regimen
The approach to virologic failure of an initial NNRTI-based or PI-based regimen has been addressed previously. 1 The approach to initial failure of an INSTI-based regimen is similar, but an integrase genotype (or combined genotype) should be included prior to discontinuation of the INSTI. Raltegravir-and elvitegravirbased regimens should be discontinued as soon as virologic failure is confirmed and resistance testing ordered to minimize accumulation of further mutations that may cause cross-resistance to dolutegravir.
134
Rates of virologic failure are comparable at 1 year for NNRTI and boosted PI regimens; however, NNRTI-based regimens were associated with more NNRTI and NRTI mutations than PI-based regimens.
135,136 Higher rates of treatment failure were also reported in patients receiving a second regimen, 137 suggesting that patients receiving second-line therapy were often nonadherent to their initial regimen. The second regimen should generally include a boosted PI because of the high barrier to resistance, especially when there is evidence of a compromised NRTI backbone. A boosted PI should be used with at least 1 fully active agent (NRTI, INSTI, or NNRTI). New evidence emerged for the use of an active NRTI backbone plus a boosted PI, an INSTI plus a boosted PI, or an INSTI plus a boosted PI after initial failure of an NNRTI-based regimen.
138,139
Multidrug Resistance
Multidrug resistance typically occurs after failure of several regimens, especially after extensive treatment with older, less potent antiretroviral drugs. Transmission of multidrug-resistant HIV is rare. Because thymidine analog NRTIs and unboosted PIs are rarely used today, extensive NRTI and PI resistance has become uncommon.
There are 5 classes of antiretroviral drugs from which to select a regimen with at least 2 fully active drugs. In the setting of multidrug resistance, inclusion of a potent boosted PI in the new regimen is recommended because of its higher barrier to resistance. In most cases, this regimen will be either 800 mg of darunavir with 100 mg of ritonavir (once daily) if there are no darunavir-associated mutations or 600 mg of darunavir with 100 mg of ritonavir (twice daily) if there are major darunavirassociated mutations. 140 Alternatively, ritonavir-boosted tipranavir may have a role in the regimen based on resistance test results. Some patients, especially those who previously experienced treatment failure with unboosted amprenavir or fosamprenavir, may have cross-resistance to darunavir but susceptibility to tipranavir. However, tipranavir is less well tolerated, requires boosting with 200 mg of ritonavir twice daily, and has complex viroc, and in exceptional circumstances the fusion inhibitor enfuvirtide. Susceptibility of etravirine is predicted by genotype or phenotype. Etravirine retains good activity against HIV with the K103N mutation, similar to activity against wild-type virus, but the presence of 3 or more etravirine mutations substantially reduces its activity, particularly the Y181C mutation. Specific mutation-weighted scoring systems to predict etravirine activity should be used. 143,144 Dosing of uncommon combinations should be checked against drug interactions and prescribing information for each drug. Studies have confirmed a role for INSTIs in patients with virologic failure and triple-class-resistant virus (ie, NRTI, NNRTI, and PI). Elvitegravir and raltegravir have comparable activity in treatmentexperienced, INSTI-naive patients.
145,146 Dolutegravir has better activity than raltegravir in ART-experienced, INSTI-naive patients, and is dosed once daily. 147 Dolutegravir should be dosed twice daily in patients who experienced treatment failure with a raltegravir-or elvitegravir-containing regimen. 148 Activity of dolutegravir is substantially reduced in the presence of the Q148 mutation plus additional INSTI mutations, including the G140 mutation.
148,149
If maraviroc is being considered, tropism should be determined because maraviroc is only active against exclusively CCR5-tropic virus. If CXCR4 or dual-mixed tropism is present, maraviroc is not suitable.
150 Maraviroc dosing varies depending on the other antiretroviral drugs in the regimen because of its metabolism by hepatic CYP 3A4 enzymes; the dose should be determined using drug interaction resources.
106
Including NRTIs with partial or no anticipated activity in a new regimen has been a common practice, but recent data suggest that omitting NRTIs from the regimen, guided by results from resistance testing, does not compromise regimen efficacy if the phenotypic susceptibility score of the drugs in the regimen is greater than 2.
151 There is no role for adding a single active agent to a failing regimen.
Switching Regimens for Toxicity, Tolerability, or Convenience
Several ART switch strategies are available to reduce or prevent toxicity and improve adherence in suppressed individuals. Switching 1 ART should be started as soon as possible, preferably within the first 2 weeks of diagnosis, in patients with opportunistic infections (AIa) and other opportunistic diseases and AIDS-defining illnesses (including all lymphomas and human papillomavirus-related cancers) (AIa-BIII).
Optimal timing of ART initiation in patients with cryptococcal meningitis is less certain, but initiating ART early during cryptococcal treatment should be considered when expert management for both cryptococcal and HIV infection is available (BIII).
Changes in Recommendations for What Treatment to Start
Dolutegravir-based regimens and co-formulated elvitegravir/cobicistat/ tenofovir/emtricitabine have been added to the list of recommended regimens for initial ART (AIa).
Co-formulated rilpivirine/tenofovir/emtricitabine has been added as an initial recommended ART regimen in patients with HIV-1 RNA levels <100 000 copies/mL (AIa).
Raltegravir plus abacavir/lamivudine has been added as an alternative initial regimen (BIa).
Atazanavir/cobicistat plus 2 nucleoside reverse transcriptase inhibitors was added as an alternative initial regimen (BIa).
Darunavir/cobicistat plus 2 nucleoside reverse transcriptase inhibitors was added as an alternative initial regimen (BIII).
Ritonavir-boosted darunavir plus abacavir/lamivudine was added as an alternative initial regimen (BIb).
Ritonavir-boosted darunavir plus raltegravir has been added as an nucleoside reverse transcriptase inhibitor-sparing alternative regimen only to be used in certain circumstances (BIb).
Ritonavir-boosted lopinavir plus lamivudine has been added as an nucleoside reverse transcriptase inhibitor-limiting alternative regimen only to be used in certain circumstances (BIb).
Changes in Recommendations for Monitoring
Level of HIV-1 RNA should be monitored approximately 4 weeks after treatment is initiated or changed, and then every 3 months to confirm suppression of viremia below the limit of quantification of sensitive commercial assays (AIa).
Once viral load has been suppressed consistently for >2 years and CD4 cell counts are consistently >500/μL, monitoring CD4 cell counts is optional unless virologic failure occurs or there are intercurrent immunosuppressive treatments or conditions (CIII). Level of HIV-1 RNA of >200 copies/mL should prompt evaluation of factors leading to failure and consideration of switching ART (AIIa).
Changes in Recommendations for Treatment-Experienced Patients
Depending on resistance, viral tropism, and available options, inclusion of a boosted protease inhibitor and agents from newer drug classes should be considered in patients with multidrug resistance (AIa).
Switching or regimen simplification in virologically suppressed individuals is generally safe if prior treatment and resistance profile are considered. Full activity of the nucleoside reverse transcriptase inhibitors is important when switching from a boosted ritonavir-boosted protease inhibitor to a drug with a lower barrier to resistance (AIa).
a Ratings of the strength of the recommendations and quality of evidence are described in Table 1 . The recommendations described herein were chosen because the recommendation is new compared with the 2012 recommendations or the recommendation has changed in some substantial way, including strength or quality of rating, compared with the 2012 recommendations.
strategy from a boosted PI to raltegravir have shown substantial improvement in lipids and a small but substantial increase in BMD.
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Switching from a multiple-tablet regimen to a fixed-dose combination pill is likely to improve convenience and maintain adherence and may also reduce cost to the patient (eg, lower co-payments). However, not all switches are successful because the activity of the accompanying drugs is a key determinant of outcome. The major consideration in switching is maintenance of potency and suppression; knowledge of archived resistance is crucial, as demonstrated in switch studies from a boosted PI to raltegravir, in which a compromised NRTI backbone increased the risk of treatment failure. 156 Although switching for reduced pillburdentofixed-dosecombinationsgenerallymaintainsvirologicsuppression,thereisariskofadverseeffectsfromthenewregimen;patients require close monitoring after the switch. Whenswitchingtherapyinpatientswithvirologicsuppression,the pretreatment viral load is less important than in ART-naive patients. Switching from efavirenz/tenofovir/emtricitabine to rilpivirine/ tenofovir/emtricitabine to relieve efavirenz-associated central nervous system adverse effects appears safe in suppressed individuals, without loss of virologic control despite the potential for subtherapeutic rilpivirine concentrations from the effect of efavirenz on CYP 3A4 enzymes in the first 2 weeks of treatment change. 157 Switches to improve dosing convenience in treatment-experienced patients include twicedaily raltegravir or a boosted PI-based or efavirenz-based regimen to once-daily elvitegravir/cobicistat/tenofovir/emtricitabine 158-160 or rilpivirine/tenofovir/emtricitabine single-tablet regimens. 161 Switching a twice-daily boosted PI to once-daily boosted darunavir (800 of darunavirwith100mgofritonavir)issafeinsuppressedindividualswith no baseline darunavir mutations.
140,162
Treatment Simplification Strategies
Few data support the efficacy of induction-maintenance strategies in which treatment is deintensified after virologic suppression has been achieved. 
Conclusions and Future Directions
New recommendations or those with increased strength, compared with the 2012 recommendations, 1 are summarized in Box 2.
Despite the success of ART and its potential for reduction of HIV transmission, the incidence of new infections in resource-rich settings remains relatively stable. 169 To date, 30% to 35% of newly diagnosed patients in high-income countries present with a CD4 cell count of less than 200/μL at diagnosis. 170 Therefore, to fully exploit the potential of ART, efforts are needed to diagnose and treat HIV infection as early as possible. In particular, diagnosis and treatment of acute and recent infection is crucial because it is a major driver of the epidemic. [171] [172] [173] The availability of new, less toxic drugs with convenient dosing facilitates widespread acceptance of early therapy. In addition, new strategies must be pursued to eliminate the HIV-associated stigma and discrimination that persist in many countries and are partially responsible for delayed care. The ultimate goal is global availability of ART for everyone in need. This is the prerequisite to reduce HIV morbidity and mortality on a global scale and to achieve control of the pandemic. Early, intensified, widespread, and uninterrupted treatment has the greatest potential to control the pandemic because a vaccine and cure are not yet within reach.
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